1. Home
  2. SGMT vs LPA Comparison

SGMT vs LPA Comparison

Compare SGMT & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • LPA
  • Stock Information
  • Founded
  • SGMT 2006
  • LPA 2013
  • Country
  • SGMT United States
  • LPA United States
  • Employees
  • SGMT N/A
  • LPA N/A
  • Industry
  • SGMT
  • LPA
  • Sector
  • SGMT
  • LPA
  • Exchange
  • SGMT Nasdaq
  • LPA Nasdaq
  • Market Cap
  • SGMT 230.3M
  • LPA 196.1M
  • IPO Year
  • SGMT 2023
  • LPA N/A
  • Fundamental
  • Price
  • SGMT $7.11
  • LPA $6.34
  • Analyst Decision
  • SGMT Strong Buy
  • LPA
  • Analyst Count
  • SGMT 7
  • LPA 0
  • Target Price
  • SGMT $26.57
  • LPA N/A
  • AVG Volume (30 Days)
  • SGMT 601.4K
  • LPA 12.7K
  • Earning Date
  • SGMT 08-13-2025
  • LPA 08-13-2025
  • Dividend Yield
  • SGMT N/A
  • LPA N/A
  • EPS Growth
  • SGMT N/A
  • LPA N/A
  • EPS
  • SGMT N/A
  • LPA 0.22
  • Revenue
  • SGMT N/A
  • LPA $45,924,457.00
  • Revenue This Year
  • SGMT N/A
  • LPA N/A
  • Revenue Next Year
  • SGMT N/A
  • LPA N/A
  • P/E Ratio
  • SGMT N/A
  • LPA $29.12
  • Revenue Growth
  • SGMT N/A
  • LPA 6.18
  • 52 Week Low
  • SGMT $1.73
  • LPA $5.71
  • 52 Week High
  • SGMT $11.41
  • LPA $15.85
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 39.46
  • LPA 49.91
  • Support Level
  • SGMT $7.01
  • LPA $6.25
  • Resistance Level
  • SGMT $7.68
  • LPA $6.47
  • Average True Range (ATR)
  • SGMT 0.51
  • LPA 0.31
  • MACD
  • SGMT -0.02
  • LPA 0.04
  • Stochastic Oscillator
  • SGMT 39.03
  • LPA 52.82

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

Share on Social Networks: